Tagged with S

Mexico Guy Savoir, CEO at Carnot Laboratorios, brings strategic vision to Mexico’s pharmaceutical reindustrialisation. Leading a company that has achieved balanced growth across Mexican and Latin American markets, he articulates an ambitious vision for North American pharmaceutical integration whilst navigating complex regulatory environments. Under his leadership, Carnot has committed 150 million…

Argentina Gustavo Pelizzari leads Elea, Argentina’s largest pharmaceutical company by sales volume, employing 1,350 people. Under his leadership, Elea has achieved the unique distinction of simultaneously leading both the retail pharmaceutical market and the high-cost speciality products segment, a feat that requires markedly different capabilities. Leveraging full vertical integration and a…

France Laurence Peyraut serves as Director General of LEEM (Les Entreprises du Médicament), France’s pharmaceutical industry association representing 270 companies ranging from small French generic manufacturers to major multinational innovators. With two years at LEEM and one year on the EFPIA Board, Peyraut is operating under unprecedented geopolitical pressures reshaping pharmaceutical…

France Estelle Fruchet, General Manager of Shionogi France since September 2024, brings 25 years of pharmaceutical experience spanning major organisations including Roche, Gilead, and Novartis Gene Therapies. A pharmacist by training with specialisation in product launches – most notably Gilead’s hepatitis C therapy – Estelle Fruchet now leads a 25-person affiliate…

Global 2025 was a year of volatility for pharma and healthcare. In particular, the speed with which the administration of Donald Trump makes (and often then changes) consequential policy decisions has left industry stakeholders in the US and globally scrambling to fall in line. There are already clear winners and losers…

USA Michael Pearlmutter, CEO of the EveryLife Foundation for Rare Diseases (the EveryLife Foundation), brings a deeply personal motivation and commitment to driving meaningful change for the rare disease community. In this conversation, Pearlmutter reflects on the Foundation’s mission, its impact across the rare disease ecosystem, and the evolving opportunities to…

Mexico Ricardo Amtmann, President of Sanfer Group, discusses the company’s evolution from a licensing-dependent operation into Latin America’s most vertically integrated pharmaceutical enterprise. With nearly 14,000 employees across the region, Sanfer has transformed through strategic acquisitions, manufacturing investments, and a principled approach to market expansion. Amtmann articulates his vision for Mexico’s…

Brazil Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology transfer agreements is bolstering local manufacturing capabilities and helping these companies scale the value chain. Multinationals – with the right…

Taiwan Dr Shuling Cheng is steering Oneness Biotech through a pivotal transition from a Taiwan-based research organisation to a globally focused commercial company. After 25 years in US biotech and medtech, she returned to Taiwan a decade ago and brought two companies to IPO on the Taipei stock exchange.  She joined…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Pfizer’s US$2.1B licensing deal with Fosun Pharma for an oral GLP-1 agonist, Bao Pharmaceuticals’ 129% surge on its HKEX debut, and Juncell’s Hong Kong IPO filing targeting China’s first TIL therapy. Biocytogen listed on Shanghai’s STAR Market for its…

Brazil Danielle Bibas leads Pierre Fabre’s operations in Brazil, overseeing three key dermo-cosmetic brands – Avène, Darrow, and Ducray – in the world’s third-largest beauty market. Since assuming the role in January 2025, she has focused on navigating the rapidly transforming skincare landscape, balancing traditional physician relationships with emerging digital channels,…

France Genethon sits at the forefront of a fast-accelerating moment in gene medicine, where decades of foundational research are now translating into clinical progress across rare liver, neuromuscular, immune and ophthalmic diseases. In this interview, Frédéric Revah reflects on the organisation’s scientific evolution, its approach to partnerships and access, and the…